A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an enhanced supportive care (ESC) clinic.
AffiliationDepartment of Acute Medicine and Critical Care, The Christie, Wilmslow Road, Manchester, UK
MetadataShow full item record
AbstractOutpatient management of low risk febrile neutropenia patients (LRFN) identified by the MASCC score is a safe and effective strategy. Early supportive care has been shown to improve outcomes in patients with care. We developed an innovative ambulatory outpatient "enhanced supportive care" (ESC) clinic combining emergency oncology and supportive care through which we incorporated the management of patients with LRFN.
CitationA novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an enhanced supportive care (ESC) clinic. 2018, Support Care Cancer
JournalSupportive Care in Cancer
- [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
- Authors: Borget I, Antoun S, Chachaty E, Gachot B, Alibay A, Di Palma M, Merad M
- Issue date: 2014 Oct
- Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
- Authors: Ahn S, Rice TW, Yeung SJ, Cooksley T
- Issue date: 2018 May
- Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
- Authors: Pherwani N, Ghayad JM, Holle LM, Karpiuk EL
- Issue date: 2015 Apr 15
- Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia.
- Authors: Bavle A, Grimes A, Zhao S, Zinn D, Jackson A, Patel B, Porea T, Dutta A, Russell H, Heczey A
- Issue date: 2018 Oct
- Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
- Authors: Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T
- Issue date: 2013 Mar 20